Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07457528) titled 'Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC' on March 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition:
Resectable Esophageal Squamous Cell Carcinoma
Intervention:
Drug: HLX10
Drug: Chemotherapy
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: March 12, 2026
Target Sample Size: 46
Countries of Recruitment:
China
To kno...